The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | A final update of ENHANCE: reflecting on the negative read-out of the study
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the Phase III ENHANCE trial (NCT04313881), which compared the efficacy and safety of magrolimab plus azacitidine versus placebo plus azacitidine in patients with frontline high-risk myelodysplastic syndromes (HR-MDS), highlighting possible reasons for the negative read-out of the trial. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
